Form D · Pharmaceuticals
Kalos Therapeutics, Inc.
San Diego, CA · CIK 0001569466
Offering snapshot reported Jan 7, 2016 · SEC filing
- Reported sold
- $100K Offering amount: $2.4M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 31, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 7, 2016 | Initial | $100,000 | No comparison | 1 | SEC filing |
| Feb 12, 2013 | Initial | $19,999 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-254756
Source: Form D, filed Jan 7, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| George Colberg | Director, Executive |
| James Merritt | Executive |
| Michael Mitrow | Director |
| Larry Stambaugh | Director |
| Derek Vest | Director |
| Gregory F. Witchel | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
4370 La Jolla Village Drive, Suite 400
San Diego, CA, 92122
San Diego, CA, 92122